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Abstract
BACKGROUND: Positron emission tomography (PET) com-
bined with computer tomography (CT) using 68Ga-DOTATATE 
is a promising method for the evaluation of patients with recog-
nised or suspected neuroendocrine tumours (NET). The aim of 
this study was to assess the diagnostic value of 68Ga-DOTATATE 
PET/CT in the visualisation of the expression of somatostatin 
receptors (SSTR) and identification of new lesions. 
MATERIAL AND METHODS: Between December 2009 and 
January 2011 ninety-seven patients with confirmed (88 cases) 
or suspected (9 cases) NET underwent 68Ga DOTATATE 
PET/CT. The primary, confirmed or suspected, NET localiza-
tions were: GEP tumours — 71 patients; medullary thyroid 
carcinoma — 4 patients; cancer of an unknown primary — 14 
patients; and NET in other localisations — 8 patients. PET/CT 
acquisitions were performed using standard techniques, 
 The diagnostic role 
of 68Ga-DOTATATE PET/CT 
in the detection of neuroendocrine 
tumours
Correspondence to: Grażyna Łapińska
Department of Nuclear Medicine and Oncological Endocrinology 
Maria Skłodowska-Curie Cancer Centre — Institute
ul. W.K. Roentegena 5, 02–781 Warsaw, Poland
Tel: +48 22 546 20 41, fax: +48 22 546 31 99 
e-mail: g-lapinska@o2.pl
45 to 60 minutes after the intravenous injection of 111–185 
MBq 68Ga-DOTATATE.
RESULTS: 68Ga-DOTATATE PET/CT detected the presence of 
lesions demonstrating the somatostatin receptor affinity in 50 of 
the 97 patients (51.5%) and was negative in 47 patients (48.5%). 
Among 14 patients with metastatic unknown primary cancer, in 
5 patients (45.5%) the primary tumour site was identified, and 
in 4 patients with medullary thyroid cancer distant metastases 
with SSTR expression were localized in only one patient. 
CONCLUSIONS: Our findings confirm the diagnostic role of 
68Ga-DOTATATE PET/CT as an accurate method of identifying 
primary tumours and distant metastases. It provides informa-
tion on tumour cell receptors status, which has a significant 
bearing on planning target radionuclide therapy. Overall, 
68Ga-DOTATATE PET/CT can be used in staging, re-staging, 
and in regular follow up of oncology patients. 
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Introduction  
Neuroendocrine tumours (NETs) constitute a rare and het-
erogeneous group of neoplasms originating from the neural 
crest [1]. They are characterized by the presence of somato-
statin receptors on their cell surface [2]. Somatostatin receptor 
scintigraphy (SRS) is regarded as one of the basic imaging 
procedures in NET patients. However, positron emission to-
mography (PET) combined with computer tomography (CT) 
has become a promising method for the evaluation of the cellular 
metabolism and expression of receptors in tumours. Recent stu-
dies have shown the superiority of PET using 68Ga-DOTA -TOC 
over somatostatin receptor scintigraphy (SRS) and diagnostic 
CT in NET detection [3, 4]. 
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68Ga-labelled somatostatin analogue peptides have proven to 
be increasingly useful in neuroendocrine tumour diagnostics due 
to several technical and biological advantages such as fast clear-
ance, rapid tissue penetration, and low antigenicity [5]. Moreover, 
they are characterised by a shorter procedure and the possibility 
of imaging the whole body.
The aim of this study was to assess the diagnostic value of 
68Ga-DOTATATE PET/CT in the visualisation of the expression 
of somatostatin receptors (SSTR) in patients with recognised or 
suspected NET. 
Material and methods
We retrospectively reviewed ninety-seven patients (57 female, 
40 male, aged 18–81 years, mean age 54 years, median 58 years) 
with confirmed (88 patients) or suspected (9 patients) NET, who 
underwent 68Ga-DOTATATE PET/CT between December 2009 
and January 2011 in our Institute. Fifty-one patients (52.6%) were 
previously examined using conventional imaging (CT, MRI, USG, 
SRS). Eighty-eight patients had histologically proven NET and 9 
patients were suspected of neuroendocrine character of malig-
nancy based on needle aspiration biopsy BAC or elevated tumour 
biomarkers levels. 
The clinical indications for examination were: detection of 
localized primary (14 patients); efficacy assessment of surgical 
resection and follow-up after therapy carried out between two 
and six months after the procedure (47 patients); detection of 
suspected recurrence or metastasis (16 patients); identification 
of somatostatin receptor expression of lesions detected in other 
investigations (8 patients); and initial tumour staging (12 patients). 
Primary tumour localizations are shown in Table 1.
68Ga–DOTATATE was synthesized at the radiochemistry sec-
tion of our department. DOTATATE (Dota-Phe1, Tyr3-octreotate) 
was obtained from IEA OR POLATOM. Gallium chloratum 
(68GaCl3) was obtained from a 
68Ge/68Ga generator eluted with 
0.6 M hydrochloric acid. A final pH of 3.5–4% was assured by 
addition of 1.25 M sodium acetate solution (AcONa). Incubation 
was carried out at 100–110oC for 15 minutes. Effluent contain-
ing the 68Ga fraction was passed through a cationic exchange 
column SepPak (C-18) to clean 68Ga from any potential 68Ge 
breakthrough and from others cations. Finally the product 
was washed with ethanol and dissolved in 0.9% saline [6]. Qual-
ity control was performed with thin-layer chromatography (TLC) 
analysis using 0.1 M trisodium citrate/02 M HCL as a mobile 
phase [7]. Radiochemical purity was higher than 95% before 
being injected into the patient.
PET/CT acquisitions were performed using a dedicated 
combined PET-16 detector CT unit (Gemini 16TF, Philips). Ima-
ges were obtained 45 to 60 minutes after the intravenous injection 
of 111–185 MBq 68Ga-DOTATATE. Additionally, patients received 
intravenously furosemide for faster elimination of the tracer. While 
awaiting their examination, patients were given an oral contrast 
agent containing 15 ml of Gastrografin. 
Whole-body examinations from brain to mid-thigh were 
performed with the patient lying supine. PET scan emission 
images were recorded for 2 minutes per bed position. Low-dose 
CT acquisition parameters were 120 kV, 50 mA, 0.5 tube rotation 
and 5 or 2 mm thickness. Image reconstruction was done with 
a 3D iterative ordered subsets expectation maximization (OSEM) 
algorithm with blob basis functions.
To calculate maximal standardized uptake values (SUVmax), 
manually defined regions of interest were drawn on the attenua-
tion-corrected emission images throughout the axial planes in le-
sions identified as areas of focally increased uptake. The SUVmax 
values were calculated according to the formula:
SUV =
Tissue concentration (Bq/g)
Injected dose (Bq) / Body weight (g)
Results
68Ga-DOTATATE PET/CT detected the presence of le-
sions demonstrating the somatostatin receptor affinity in 50 of 
the 97 patients (51.5%) and was negative in the remaining 47 
patients (48.5%). 
From the group of 51 patients who underwent other con-
ventional imaging before PET/CT scan, in 32 cases (63%) find-
ings were concordant with previous studies, in 14 patients (27%) 
new lesions were found, and in 5 patients (10%) lesions detected 
in other investigations did not reveal SSRT expression. From those 
5 patients, subsequent diagnostic did not confirm neuroendocrine 
character of the tumour in 4 patients (3 cases with liver metas-
tases in CUP; 1 patient with suspected gastrinoma), and in the 
remaining case there was an absence of further data. Those 5 
patients belong to the group of 9 patients with suspicion of NET. 
In the remaining 4 of the 9 patients in this group 68Ga-DOTATATE 
revealed receptor expression in lesions that confirmed neuroen-
docrine character of neoplastic disease. 
Only 5 of the 97 patients had previously undergone so-
matostatin receptor scintigraphy. In 3 of them our examination 
was discordant with SRS and revealed more information: 1 — new 
metastases in liver; 1 — new metastases in bones; and 1 — exclu-
sion of recurrence in postoperative region.
In 46 of the 97 patients no previous imaging examinations were 
performed. The main indication for PET investigation was efficacy 
assessment of surgical resection or follow-up after therapy. In 
this group in 33 patients (72%) no pathological lesions were 
detected. 68Ga-DOTATATE was positive in the remaining 13 pa-
tients (28%). 







   Stomach 9 2
   Small intestine (appendix) 31 (21)
   Pancreas 10 3
   Colon 15 1
Medullary thyroid carcinoma 4
Cancer of unknown primary 11 3
NET in other localization 8
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Among 4 patients with medullary thyroid cancer after opera-
tion (indicative of rising level of calcitonin) distant metastases with 
SSTR expression (pancreas and retroperitoneal lymph nodes) were 
detected in only one patient.  
68Ga-DOTATATE PET/CT performed in 14 of the 97 patients with 
metastatic unknown primary cancer (liver and lungs) was nega-
tive in 3 patients as the lesions did not take up the tracer and 
histopathological verification did not confirm preliminary diagnosis. 
In the remaining 11 patients with PET/CT-positive findings, in 6 
patients (6/11 — 54.5%) no primary tumour site was detected, and 
in 5 patients (5/11 — 45.5%) 68Ga-DOTATATE PET/CT depicted the 
primary tumour (small intestine — 2; colon — 1; pancreas — 1; 
ovary — 1). 
In order to improve the evaluation of the SST receptor expres-
sion in further practice, standardised uptake values (SUVmax) were 
measured using 68Ga-DOTATATE PET/CT results regarding normal 
biodistribution of the tracer in all patients included in the study. 
The average SUVmax values and their range shown in Table 2 are 
concordant with results obtained in other studies [8, 9].
Discussion
In recent decades neuroendocrine tumour detection 
has significantly increased due to the development of imaging 
techniques and highly specific radiopharmaceuticals for PET 
studies [2]. 
Previously used conventional imaging (ultrasonography, 
computed tomography (CT), or magnetic resonance imaging 
(MRI)) allowed the detection of primary tumours and metastatic 
lesions in 40–60% of patients [10]. Neuroendocrine tumours, par-
ticularly those of the gastro-intestinal tract, frequently express high 
levels of somatostatin receptors; therefore, radioisotope imaging 
techniques with somatostatin analogues labelled with 111In or 99mTc 
proved to be considerably more sensitive (60–90% depending on 
the tumour type) in visualization of lesions [3, 11–14].
Our study has demonstrated that in 50 patients (51.5%) 
68Ga-DOTATATE depicted lesions with an affinity to SSTR. In 
this group, SSTR expression presence confirmed neuroendocrine 
character of the neoplasm in 4 patients with previously suspected 
NET.
In 51 of the 97 patients who previously underwent conventional 
imaging procedures, 68Ga-DOTATATE confirmed the presence of 
lesions. Additionally, in 32 patients (63%) those lesions indicated 
SSRT expression. The obtained data affected the treatment plan, 
and most of all indicated possibilities for peptide receptor radio-
nuclide therapy.
More recently, Ambrosini et al. [15] studied 90 patients with 
histological confirmation of NET, who underwent 68Ga-DO-
TANOC and CT scan. PET/CT findings were concordant with 
conventional imaging in 52.2% of cases and discordant in 
46.7%, which resulted in stage modification in 28.6% of the 
patients from this group. 
PET imaging offers great diagnostic value in different types of 
tumours. Its ability to combine high sensitivity with reasonable 
resolution and whole-body scans enables the detection of more 
lesions [16]. 
68Ga-DOTATATE PET/CT provides additional information and 
is more accurate than conventional imaging procedures in visu-
alization of NET [17, 18]. Our study has also shown improvement 
in diagnostic performance of PET/CT imaging of NET. In 14 of 
the 51 patients (27%) more lesions were identified compared to 
previously carried out conventional imaging.  
Table 2. SUVmax values in organs with physiological uptake
Organ Pituitary gland Parotid gland Thyroid Liver Spleen Stomach Adrenals Kidneys
SUVmax average 4.65 ± 1.9 2.69 ± 1.2 2.52 ± 1.1 5.67 ± 1.8 16.93 ± 4.5 4.8 ± 2.1 9.11 ± 2.7 11.64 ± 3.9
SUVmax range 1.2–10.1 0.4–6 0.8–6 1.6–9.3 4–26 0.2–9.8 3.8–16.8 4.3–23.7
Figure 1. A 71-year-old man with colon carcinoid after surgery. The scan was carried out due to the suspicion of distant metastases. 
A. MIP (maximum intensity projection) image shows multiple lesions with positive uptake of 68Ga-DOTATATE tracer. B. Small lesion behind  right 
eyeball. C. Multiple hepatic metastases (in segment 7 with central necrosis). D. Lesion in pancreas. E. Soft tissue mass in peritoneum (probably 
lymph node). F. Lesion in right iliac bone.
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The usefulness of PET/CT in the localization of the primary 
site in patients with metastatic cancer of unknown origin has pre-
viously been reported in the literature [19, 20]. Routinely used 
in PET, fluorodeoxyglucose (FDG) reflects the expression of in-
creased glucose metabolism in cancer cells. The FDG-PET scan 
demonstrates increased metabolic activity within the lesions. It 
can be applied especially in poorly differentiated neuroendocrine 
carcinomas, which lose their receptors. Most slow growing, 
well-differentiated neuroendocrine tumours can be characterized 
by low glucose utilization, which results in limited FDG usefulness 
[1, 21]. Radiolabelled peptides improve the detection of metastas-
es, up to as much as 82% compared to 66% for FDG PET/CT [22]. 
In our study, among 14 patients who suffered metastatic can-
cer of unknown primary, in 3 cases 68Ga-DOTATATE was negative 
(low tracer uptake) and final histopathological verification did 
not confirm neuroendocrine character of malignancy. In 5 of the 
14 patients (45.5%) 68Ga-PET/CT could localize the site of the 
primary tumour. In the remaining 6 patients the primary tumour 
site remained occult. 
According to recent studies, FDG PET/CT depicted the primary 
tumour in 33% [23] and 39% [20] of cases whereas 68Ga-DO-
TANOC could identify the site of the primary tumour in 59% of 
patients [19]. 
In patients with medullary thyroid carcinoma (MTC), with 
elevated levels of calcitonin and carcinoembryonic antigen, the 
detection of metastases proves to be highly difficult.
Widely used conventional radiological methods such as mag-
netic resonance imaging, computed tomography, or ultrasonog-
raphy can be characterised by low sensitivity derived from their 
failure to localize the residual or recurrent disease [24].
Radioisotope methods have also proven to be insufficient in 
visualization of metastases. The sensitivity of 131I-MIBG (meta-io-
dobenzyl-guanidine) for the detection of MTC is 29–30% [25], and 
the sensitivity of SRS ranges from 25 to 50% [5, 26]. 
Our findings also demonstrate the low efficacy of somatostatin 
receptor imaging. It was possible to visualize metastases in only 
1 of the 4 patients with MTC. 
In our study population, 46 of the 97 patients who underwent 
68Ga-DOTATATE PET/CT had not been subjected to any previ-
ous imaging. Based on those findings, it is difficult to assess the 
efficacy of 68Ga-DOTATATE PET/CT as a diagnostic method. 
In those cases the main purpose of the investigation was the 
evaluation of surgical tumour resection and follow-up after 
therapy as the group consisted mainly of patients after surgery. 
Thirteen patients (28%) had positive 68Ga-DOTATATE PET/CT, 
which was confirmed by further diagnostics or surgery. A group 
of 33 patients (78%) with negative 68Ga-DOTATATE PET/CT re-
mains under observation. 
Our experience shows that lesion receptor expression evalu-
ation in organs with physiological uptake of tracer (especially in 
the pancreas) and non-specific bowel uptake may mimic focal 
tumour disease, which impedes accurate diagnostic interpretation. 
Conclusions
Our findings indicate that 68Ga-DOTATATE PET/CT is an ac-
curate method for identifying primary tumours and distant me-
tastases. It provides information on tumour cell receptor status, 
which has a significant bearing on planning target radionuclide 
therapy. Moreover, it facilitates the evaluation of tumour recurrence 
and efficacy of therapeutic interventions. Overall, 68Ga-DOTATATE 
PET/CT can be used in staging, re-staging, and in regular follow 
up of oncology patients.
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